Stocksigma LogoStocksigma Logo

Alembic Pharmaceuticals Receives USFDA Final Approval for Olopatadine Hydrochloride Ophthalmic Solution

Alembic Pharmaceuticals has secured USFDA final approval for its ANDA Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), therapeutically

Alembic Pharmaceuticals Receives USFDA Final Approval for Olopatadine Hydrochloride Ophthalmic Solution

Alembic Pharmaceuticals Ltd 路 Press Release 路 05 Nov 2026, 3:26 am

Alembic Pharmaceuticals Receives USFDA Final Approval for Olopatadine Hydrochloride Ophthalmic Solution Alembic Pharmaceuticals has secured USFDA final approval for its ANDA Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), therapeutically equivalent to Alcon鈥檚 Pataday Once Daily Relief. Developed with Orbicular Pharmaceutical Technologies, the product targets itchy eyes relief, addressing an estimated US market size of US$20 million for the 12 months ending Sep'26. This approval increases Alembic鈥檚 cumulative USFDA tally to 248 ANDA approvals, comprising 229 final approvals and 19 tentative approvals.

Original exchange filing (PDF)

More announcements from Alembic Pharmaceuticals Ltd

All Alembic Pharmaceuticals Ltd announcements